T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: implications for...

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Inflammatory arthritis (IA) is a spectrum of disease, from at-risk stages to rheumatoid arthritis (RA) and remission.
• T-cell dysregulation is central to RA, yet T-cell phenotypes across the IA continuum are understudied.
• Understanding T-cell subsets can reveal disease progression mechanisms.

Purpose of the Study:

• To investigate CD4+ T-cell subset disturbances (naïve, regulatory, inflammation-related cells) across the IA continuum.
• To develop a predictive risk-score for disease progression using these T-cell subsets.
• To assess the score's efficacy in predicting transitions between IA stages, including RA development and remission flares.

Main Methods:

• Analyzed T-cell subsets (naïve, regulatory, IRC CD4+ T-cells) in 705 individuals across the IA continuum.
• Developed a simple risk-score based on the presence/absence of risk-associated T-cell subsets.
• Validated the risk-score's predictive power for progression between stages: at-risk to IA, evolving IA to RA, untreated RA to remission, and RA remission to flare.

Main Results:

• The risk-score, incorporating naïve and regulatory T-cells, accurately predicted progression from at-risk to IA (p < 0.0001).
• The score also predicted RA development in evolving IA patients (p < 0.0001) and treatment-induced remission in untreated RA patients (OR 15.4, p < 0.0001).
• Naïve CD4+ T-cells were consistently predictive of progression across the entire IA continuum, including predicting flares in RA patients in remission (p < 0.0001).

Conclusions:

• A simple risk-score based on CD4+ T-cell subsets effectively predicts disease progression throughout the inflammatory arthritis continuum.
• Naïve CD4+ T-cells are key predictors of progression and flares in rheumatoid arthritis.
• This risk-stratification approach enables early identification of high-risk individuals for timely, targeted therapeutic interventions, potentially improving patient outcomes.